NDANASALAEROSOL, METERED
Approved
Mar 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
QNASL (beclomethasone dipropionate) by Teva is anti-inflammatory activity. First approved in 2012.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QNASL is a nasal aerosol formulation of beclomethasone dipropionate, a corticosteroid approved in 2012 for treating allergic rhinitis and other nasal inflammatory conditions. It works through rapid conversion to its active metabolite 17-BMP, which binds the glucocorticoid receptor with high affinity (~13x dexamethasone) to suppress inflammatory cells and mediators including mast cells, eosinophils, and cytokines. The formulation is designed to deliver topical anti-inflammatory activity with minimal systemic corticosteroid effects at recommended doses.
$0.005BPart D
Peak5.1 years to LOEStable peak-phase product with modest Part D utilization (~11k claims annually) suggests established but niche market position with smaller commercial teams than growth-stage assets.
Mechanism of Action
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®
Started Apr 2023
69 enrolled
Asthma
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
Started Mar 2019
1,550 enrolled
Bronchial Asthma
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
Started Jun 2018
366 enrolled
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
Started Sep 2015
713 enrolled
Persistent Asthma
Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
Started May 2015
1,479 enrolled
Chronic Obstructive Pulmonary Disease
Worked on QNASL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.